Terence Rooney, MD

Chief Medical Officer

Terence is Chief Medical Officer at Kymera Therapeutics, where he leads global clinical development strategy and the advancement of Kymera’s oral immunology portfolio across multiple immuno-inflammatory diseases. Prior to joining Kymera, Terence served as Senior Vice President, Portfolio and Asset Management Leader, Immunology, at Johnson & Johnson, where he led global compound development teams and portfolio strategy and operations across immunology. Earlier in his career, he held senior leadership roles across immunology R&D at Eli Lilly and Roche, including work at the interface of discovery, translational medicine and clinical development. Across his career, his work has spanned small molecules, peptides, biologics and cell therapies, combination and precision therapy strategies, and therapeutic areas including dermatology, respiratory, rheumatology, gastroenterology and rare diseases. Terence has contributed to successful marketing applications for groundbreaking medicines including ICOTYDE®, IMAAVY®, OLUMIANT®, STELARA®, and TREMFYA®.

Terence received his medical degrees from the Royal College of Surgeons in Ireland. He completed his training in internal medicine at the Dublin Academic Teaching Hospitals in Ireland, and rheumatology fellowships both there and at the University of California, San Francisco. He received a doctorate from the National University of Ireland and has authored some 50 peer-reviewed scientific publications.